Entia Biosciences, Inc. (ERGO)
- Previous Close
0.0001 - Open
0.0001 - Bid --
- Ask --
- Day's Range
0.0001 - 0.0001 - 52 Week Range
0.0001 - 0.0002 - Volume
15,000 - Avg. Volume
328 - Market Cap (intraday)
235,627 - Beta (5Y Monthly) 11.41
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.
www.entiabio.comRelated News
Performance Overview: ERGO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ERGO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ERGO
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
0.89
Enterprise Value/EBITDA
-0.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-164.37%
Return on Equity (ttm)
--
Revenue (ttm)
265.47k
Net Income Avi to Common (ttm)
-1.4M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
76.05k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-290.65k
Company Insights: ERGO
ERGO does not have Company Insights